Thrivent Financial For Lutherans increased its position in shares of GenMark Diagnostics, Inc. (NASDAQ:GNMK) by 65.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 526,860 shares of the medical equipment provider’s stock after buying an additional 208,000 shares during the period. Thrivent Financial For Lutherans owned about 0.96% of GenMark Diagnostics worth $6,232,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in GNMK. Teachers Advisors LLC increased its stake in shares of GenMark Diagnostics by 6.1% during the fourth quarter. Teachers Advisors LLC now owns 98,220 shares of the medical equipment provider’s stock valued at $1,202,000 after buying an additional 5,652 shares during the period. Nationwide Fund Advisors increased its stake in shares of GenMark Diagnostics by 3.9% during the first quarter. Nationwide Fund Advisors now owns 25,936 shares of the medical equipment provider’s stock valued at $332,000 after buying an additional 981 shares during the period. Bank of New York Mellon Corp increased its stake in shares of GenMark Diagnostics by 3.3% during the first quarter. Bank of New York Mellon Corp now owns 204,928 shares of the medical equipment provider’s stock valued at $2,627,000 after buying an additional 6,482 shares during the period. TD Asset Management Inc. increased its stake in shares of GenMark Diagnostics by 3.1% during the first quarter. TD Asset Management Inc. now owns 102,074 shares of the medical equipment provider’s stock valued at $1,309,000 after buying an additional 3,074 shares during the period. Finally, Ameriprise Financial Inc. purchased a new position in shares of GenMark Diagnostics during the first quarter valued at $435,000.

Shares of GenMark Diagnostics, Inc. (GNMK) opened at 9.52 on Monday. The company’s market cap is $520.43 million. The company’s 50-day moving average price is $9.81 and its 200-day moving average price is $11.85. GenMark Diagnostics, Inc. has a 12 month low of $8.88 and a 12 month high of $13.67.

GenMark Diagnostics (NASDAQ:GNMK) last issued its quarterly earnings results on Tuesday, August 1st. The medical equipment provider reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.05). GenMark Diagnostics had a negative return on equity of 109.89% and a negative net margin of 111.96%. The company had revenue of $12.36 million for the quarter, compared to analysts’ expectations of $12.44 million. During the same quarter last year, the company earned ($0.30) EPS. GenMark Diagnostics’s revenue for the quarter was down 1.2% compared to the same quarter last year. Equities analysts forecast that GenMark Diagnostics, Inc. will post ($1.06) EPS for the current fiscal year.

In other GenMark Diagnostics news, CFO Scott Mendel sold 2,898 shares of the company’s stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $9.45, for a total transaction of $27,386.10. Following the sale, the chief financial officer now owns 138,096 shares in the company, valued at approximately $1,305,007.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Hany Massarany sold 8,311 shares of the company’s stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $9.45, for a total value of $78,538.95. Following the sale, the insider now owns 372,797 shares in the company, valued at approximately $3,522,931.65. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 55,986 shares of company stock worth $517,941. 7.50% of the stock is owned by company insiders.

GNMK has been the topic of several research reports. Canaccord Genuity restated a “buy” rating and set a $14.00 price target (down previously from $17.00) on shares of GenMark Diagnostics in a research note on Monday, August 7th. Bank of America Corporation initiated coverage on GenMark Diagnostics in a research note on Monday, September 18th. They set a “buy” rating and a $13.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $15.00 price target (down previously from $17.00) on shares of GenMark Diagnostics in a research note on Wednesday, September 13th. BTIG Research restated a “buy” rating and set a $13.00 price target on shares of GenMark Diagnostics in a research note on Thursday, August 31st. Finally, ValuEngine upgraded GenMark Diagnostics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $14.33.

TRADEMARK VIOLATION WARNING: “Thrivent Financial For Lutherans Increases Stake in GenMark Diagnostics, Inc. (GNMK)” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/09/25/thrivent-financial-for-lutherans-increases-stake-in-genmark-diagnostics-inc-gnmk.html.

GenMark Diagnostics Profile

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Institutional Ownership by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.